Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

198 sites for NCT03267433

CCND1 Expression, +4 more biomarkers

Mantle Cell Lymphoma

autologous hematopoietic stem cell transplantation, +2 more drugs

cellular therapy, +2 more types

Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

557 sites for NCT03737981

CD19 Expression, +2 more biomarkers

Chronic Lymphocytic Leukemia

ibrutinib, +2 more drugs

chemotherapy, +2 more types

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

144 sites for NCT04546399

CD19 Expression, +1 more biomarker

B-Cell Acute Lymphoblastic Leukemia

blinatumomab, +7 more drugs

chemotherapy, +2 more types

A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia

64 sites for NCT04307576

ABL1 Fusion, +11 more biomarkers

Acute Lymphoblastic Leukemia

blinatumomab, +7 more drugs

chemotherapy, +3 more types

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

1 site for NCT04998669

CD19 Expression, +1 more biomarker

Follicular Lymphoma

loncastuximab tesirine, +1 more drug

chemotherapy, +1 more type

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

54 sites for NCT03876769

CD19 Expression

B-Cell Acute Lymphoblastic Leukemia

tisagenlecleucel

cellular therapy, +1 more type

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

1 site for NCT04881240

CD19 Expression

Leukemia

allogeneic CD19-CAR CD45RA-negative T-cells, +3 more drugs

cellular therapy, +3 more types

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

35 sites for NCT04404660

CD19 Expression

B-Cell Acute Lymphoblastic Leukemia

AUTO1

cellular therapy, +1 more type

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

1 site for NCT00923013

CD19 Expression, +3 more biomarkers

Hairy Cell Leukemia, +1 more condition

cladribine, +1 more drug

chemotherapy, +1 more type

Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenström's Macroglobulinemia

12 sites for NCT04263480

CD19 Expression, +4 more biomarkers

Waldenstrom Macroglobulinemia

carfilzomib, +1 more drug

chemotherapy, +1 more type

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

12 sites for NCT04077723

CD19 Expression, +1 more biomarker

Diffuse Large B-Cell Lymphoma, +2 more conditions

glofitamab, +2 more drugs

immunotherapy

CD19-specific CAR-T Cells in CLL/SLL and DLBCL

19 sites for NCT03960840

CD19 Expression

Acute Lymphoblastic Leukemia, +3 more conditions

ibrutinib, +1 more drug

cellular therapy, +2 more types